ClinConnect ClinConnect Logo
Search / Trial NCT05080010

Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma

Launched by SUN YAT-SEN UNIVERSITY · Oct 2, 2021

Trial Information

Current as of June 06, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how effective three cycles of chemotherapy, known as CEV, are for treating high-risk retinoblastoma in children who have had one eye removed (a procedure called enucleation). The study focuses on patients with Stage I retinoblastoma, which is an early stage of this eye cancer, to see if this treatment can help improve their outcomes after surgery.

To participate in the trial, children must have a confirmed diagnosis of retinoblastoma, have undergone enucleation of the affected eye, and be able to provide consent for the study. They must not have any previous treatments for retinoblastoma in the study eye or have participated in other clinical trials recently. If eligible, participants will receive the chemotherapy and will be monitored closely throughout the study to track their progress and any side effects. This trial is currently recruiting participants of all ages and genders, aiming to improve treatments for this serious condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Ability to provide written informed consent and comply with study assessments for the full duration of the study.
  • Definite pathology signs of retinoblastoma, Stage I base on International Retinoblastoma Staging System.
  • Received enucleation in the study eye.
  • Monocular retinoblastoma.
  • Exclusion Criteria:
  • Any previous disease in the study eye.
  • Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals).
  • History of chemical intervention for retinoblastoma in the study eye.

About Sun Yat Sen University

Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.

Locations

Guangzhou, Guangdong, China

Patients applied

0 patients applied

Trial Officials

Huasheng Yang, M.D, PHD

Study Chair

Zhongshan Ophthalmic Center, Sun Yat-sen University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials